OBJECTIVES: We aimed to determine the consistency of quantitative PET measurements of metabolic tumor volume (MTV) and intratumoral heterogeneity index for primary untreated pancreatic adenocarcinomas, when using dual-time point F-FDG PET/CT imaging. METHODS: This is an institutional review board-approved, retrospective study including 71 patients with pancreatic adenocarcinoma, who underwent dual-time point F-FDG PET/CT imaging, at approximately 1 hour (early) and 2 hours (delayed), after injection. Automated gradient-based and 50% SUVmax-threshold segmentation methods were used to assess the primary tumor MTV and metabolic intratumoral heterogeneity index, calculated as the area under cumulative SUV-volume histograms (AUC-CSH), with lower AUC-CHS indexes corresponding to higher degrees of tumor heterogeneity. We defined that more than a ±10% change in MTV or AUC-CSH, compared with baseline, as clinically significant. RESULTS: Seventy-one FDG-avid pancreatic tumors were identified, with an average tumor diameter of 3.4 ± 0.9 cm (range, 1.5-6.4 cm). Metabolic tumor volume values remained consistent between early and delayed imaging when using the gradient PET segmentation method (P = 0.086), whereas statistically significant change was seen when using 50% SUVmax-threshold segmentation (P < 0.001). A decrease in more than 10% change in MTV (% ΔMTV) was observed in 70.4% (50/71) tumors, and 7.0% (5/71) of the tumors showed an increase more than 10 % ΔMTV, when using the 50% SUVmax-threshold segmentation. AUC-CSH indexes showed statistically significant differences between early and delayed time points (P < 0.001), when using the gradient segmentation. AUC-CSH index decreased by 10% or greater in 40.8% (29/71) of the tumors. AUC-CSH index remained stable between early and delayed when using the 50% SUVmax-threshold segmentation (P = 0.148) with percentage of change of less than 10% for all tumors. CONCLUSIONS: Metabolic tumor volume was relatively stable between early and delayed time points when PET gradient segmentation was used but changed greater than 10% in 77.4% of the tumors at delayed time point when threshold segmentation was used. The tumor heterogeneity index (AUC-CSH) changed greater than 10% in 40.8% of tumors at delayed imaging, when gradient segmentation was used but remained stable when threshold segmentation was used. It is important to standardize uptake time and segmentation methods to use FDG PET MTV and heterogeneity index as imaging biomarkers.
OBJECTIVES: We aimed to determine the consistency of quantitative PET measurements of metabolic tumor volume (MTV) and intratumoral heterogeneity index for primary untreated pancreatic adenocarcinomas, when using dual-time point F-FDG PET/CT imaging. METHODS: This is an institutional review board-approved, retrospective study including 71 patients with pancreatic adenocarcinoma, who underwent dual-time point F-FDG PET/CT imaging, at approximately 1 hour (early) and 2 hours (delayed), after injection. Automated gradient-based and 50% SUVmax-threshold segmentation methods were used to assess the primary tumorMTV and metabolic intratumoral heterogeneity index, calculated as the area under cumulative SUV-volume histograms (AUC-CSH), with lower AUC-CHS indexes corresponding to higher degrees of tumor heterogeneity. We defined that more than a ±10% change in MTV or AUC-CSH, compared with baseline, as clinically significant. RESULTS: Seventy-one FDG-avid pancreatic tumors were identified, with an average tumor diameter of 3.4 ± 0.9 cm (range, 1.5-6.4 cm). Metabolic tumor volume values remained consistent between early and delayed imaging when using the gradient PET segmentation method (P = 0.086), whereas statistically significant change was seen when using 50% SUVmax-threshold segmentation (P < 0.001). A decrease in more than 10% change in MTV (% ΔMTV) was observed in 70.4% (50/71) tumors, and 7.0% (5/71) of the tumors showed an increase more than 10 % ΔMTV, when using the 50% SUVmax-threshold segmentation. AUC-CSH indexes showed statistically significant differences between early and delayed time points (P < 0.001), when using the gradient segmentation. AUC-CSH index decreased by 10% or greater in 40.8% (29/71) of the tumors. AUC-CSH index remained stable between early and delayed when using the 50% SUVmax-threshold segmentation (P = 0.148) with percentage of change of less than 10% for all tumors. CONCLUSIONS:Metabolic tumor volume was relatively stable between early and delayed time points when PET gradient segmentation was used but changed greater than 10% in 77.4% of the tumors at delayed time point when threshold segmentation was used. The tumor heterogeneity index (AUC-CSH) changed greater than 10% in 40.8% of tumors at delayed imaging, when gradient segmentation was used but remained stable when threshold segmentation was used. It is important to standardize uptake time and segmentation methods to use FDG PET MTV and heterogeneity index as imaging biomarkers.
Authors: Jianhua Yan; Jason Lim Chu-Shern; Hoi Yin Loi; Lih Kin Khor; Arvind K Sinha; Swee Tian Quek; Ivan W K Tham; David Townsend Journal: J Nucl Med Date: 2015-07-30 Impact factor: 10.057
Authors: Alin Chirindel; Krishna C Alluri; Muhammad A Chaudhry; Richard L Wahl; Timothy M Pawlik; Joseph M Herman; Rathan M Subramaniam Journal: AJR Am J Roentgenol Date: 2015-05 Impact factor: 3.959
Authors: Shailesh V Shrikhande; Jörg Kleeff; Carolin Reiser; Jürgen Weitz; Ulf Hinz; Irene Esposito; Jan Schmidt; Helmut Friess; Markus W Büchler Journal: Ann Surg Oncol Date: 2006-10-25 Impact factor: 5.344
Authors: Gary J R Cook; Connie Yip; Muhammad Siddique; Vicky Goh; Sugama Chicklore; Arunabha Roy; Paul Marsden; Shahreen Ahmad; David Landau Journal: J Nucl Med Date: 2012-11-30 Impact factor: 10.057
Authors: C J Yeo; J L Cameron; K D Lillemoe; J V Sitzmann; R H Hruban; S N Goodman; W C Dooley; J Coleman; H A Pitt Journal: Ann Surg Date: 1995-06 Impact factor: 12.969
Authors: Abhinav K Jha; Esther Mena; Brian Caffo; Saeed Ashrafinia; Arman Rahmim; Eric Frey; Rathan M Subramaniam Journal: J Med Imaging (Bellingham) Date: 2017-03-03
Authors: Hunter C Gits; Amy H Tang; William S Harmsen; William R Bamlet; Rondell P Graham; Gloria M Petersen; Thomas C Smyrk; Amit Mahipal; Roman O Kowalchuk; Jonathan B Ashman; William G Rule; Dawn Owen; Michelle A Neben Wittich; Robert R McWilliams; Thorvardur Halfdanarson; Wen Wee Ma; Terence T Sio; Sean P Cleary; Mark J Truty; Michael G Haddock; Christopher L Hallemeier; Kenneth W Merrell Journal: J Gastrointest Oncol Date: 2021-10
Authors: Ana María Garcia-Vicente; David Molina; Julián Pérez-Beteta; Mariano Amo-Salas; Alicia Martínez-González; Gloria Bueno; María Jesús Tello-Galán; Ángel Soriano-Castrejón Journal: Ann Nucl Med Date: 2017-09-08 Impact factor: 2.668
Authors: Ziping Liu; Joyce C Mhlanga; Richard Laforest; Paul-Robert Derenoncourt; Barry A Siegel; Abhinav K Jha Journal: Phys Med Biol Date: 2021-06-14 Impact factor: 3.609